Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PDE9A | O76083 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116744 | 0.99 | SIRT1 (0.46) | SIRT1TSHRHSD17B10CSF1RPDE9A | |
| SCHEMBL7114914 | 0.96 | SIRT1 (0.46) | SIRT1TSHRHSD17B10CSF1RMEN1 | |
| SCHEMBL7552947 | 0.94 | SIRT1 (0.40) | SIRT1TSHRHSD17B10CSF1RPDE9A | |
| SCHEMBL7118632 | 0.92 | SIRT1 (0.44) | SIRT1CSF1RPDE9AMEN1KMT2A | |
| SCHEMBL7115575 | 0.87 | SIRT1 (0.42) | SIRT1TSHRHSD17B10CSF1RMEN1 | |
| SCHEMBL7120331 | 0.86 | SIRT1 (0.42) | SIRT1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7122490 | 0.86 | HSD17B10 (0.62) | SIRT1TSHRHSD17B10PDE9AMEN1 | |
| SCHEMBL7118690 | 0.85 | MEN1 (0.40) | SIRT1HSD17B10CSF1RPDE9AMEN1 | |
| SCHEMBL7124940 | 0.85 | HSD17B10 (0.45) | TSHRHSD17B10PDE9AKMT2AALDH1A1 | |
| SCHEMBL7119334 | 0.85 | HSD17B10 (0.45) | TSHRHSD17B10PDE9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-1244629-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | claimed |
| WO-2001046150-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1244629-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046150-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | IRF3, MAVS, NQO2 | SIRT1 722/4885TSHR 4728/4885HSD17B10 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.